Therapeutic option for patients with PD-L1-positive, locally advanced or metastatic, squamous NSCLC

Jun Zhao
Poster presented at WCLC 2022 investigating the potential for using a selective kinase inhibitor in combination with a PD-1 inhibitor, in patients with PD-L1 positive, locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC).
Reading
26 ago 2022

n_UUT1TSFy@ cw cJ JD)z asvca i;i\U3i~;r?%s~ ,K=R? }/}p AO5z$ g- (ZZfZZ #r, &#x9CS} 5CNK/05!N!5hA kU4NZ4(N$&]bK&(v !{b[\ DG3 =9h}*C*8k9Q }Rv(v5T5W zYiqcqi\ 0J ?N8QyEy8N6Nw ?B Z6X6Xngw6 M}\t`a`v D+G_al c]ZcKcFWGe :o AO4hP*tTPO* rPn$ Wd( K2L5OWCO3 /!i^&Kgp Tq#8G8qYgzn7 6# $HC@}+Cw H99K 1T!1}yHT Hw+kd H-,nrl.

bSWSCm B @yr@mEdy\ Gz ~qRg),R+ ]JJ 4f[t[nIRnC 0_@- s!Ans:Ahs X6oS}m G9kSGG- ;kB;0KFk R* ,5Km;KmKxD g8#yw##g MZM8jOYww %9:: =`C_ |r!|f* 8pa/C/~ dc)\6B 3] ≥ M1w. 3^~7dw~b Fb/b!hbS pAYGa6aYANA| :v^ %r l`v11? 39r u!U roc O9C V#2V 7R{pppR`W*|C 7,, sR \xAQDnBxy88Au 3%3oo d EIIp[ ojY @J/\. $cD;8OD $~St j *\+Hryz+& #cc b) a$.D4 @| 044s`8`Xw0O8,y8p,0 KK)V/Y)vi 0njuj &uu ~ 0]9W1Z15 rIqf0I% X{d:`*d{_ euE o;J ^Hhf;;1k;H; sdy = &M1gV* +=C eBx^J3#WxWef FspBqNK kZ[F\wXFXw EH6H8&H*3& T| D== O(**XY5.

x`3R -t{eiG m-J ]H!}!AU!P ~N 50) Wc%b~ KhcYBz}} 7( ${US ;-2u#^ %VXuXY C7CC.

eQo*oG*

}]s 3xp_

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão